Literature DB >> 1890549

The vascularity of primary cutaneous melanoma.

M E Fallowfield1, M G Cook.   

Abstract

In primary cutaneous malignant melanoma, the vascularity of the dermis immediately deep to the lesion may relate to tumour aggressiveness and to prognosis. These newly formed dermal vessels are incorporated into the melanoma to form the tumour microcirculation. We have assessed the percentage vascular volume in a series of primary melanomas in order to investigate the relationship between tumour vascularity and maximum tumour thickness. For the 64 melanomas included in this study, there appeared to be a significant relationship between the percentage vascular volume and the maximum tumour thickness. This relationship was not influenced by the presence of necrosis, vascular invasion, regression, or lymphocytic infiltrate, nor by the growth phase of the tumour. However, the percentage vascular volume was very low in the occasional thick melanoma, at least one of which was associated with prolonged survival. It seems possible that a low tumour vascularity could correlate with a relatively favourable outcome in cutaneous melanoma.

Entities:  

Mesh:

Year:  1991        PMID: 1890549     DOI: 10.1002/path.1711640309

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  Interval sentinel lymph nodes in melanoma: a digital pathology analysis of Ki67 expression and microvascular density.

Authors:  Christian Marinaccio; Giuseppe Giudice; Eleonora Nacchiero; Fabio Robusto; Giuseppina Opinto; Gaetano Lastilla; Eugenio Maiorano; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2015-08-15       Impact factor: 3.984

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

Review 3.  Intratumor microvessel density as a prognostic factor in cancer.

Authors:  N Weidner
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

4.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

Review 5.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

Review 6.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Tumour vascularity and basement membrane structure in breast cancer as related to tumour histology and prognosis.

Authors:  P Lipponen; H Ji; S Aaltomaa; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Authors:  Iris Helfrich; Inka Scheffrahn; Sönke Bartling; Joachim Weis; Verena von Felbert; Mark Middleton; Masahi Kato; Süleyman Ergün; Helmut G Augustin; Dirk Schadendorf
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

9.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

10.  Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas.

Authors:  Karina B Salgado; Nadima V Toscani; Leonardo L M Silva; Arlete Hilbig; Ligia Maria Barbosa-Coutinho
Journal:  Clin Exp Metastasis       Date:  2007-06-13       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.